These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 34626362)

  • 21. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection.
    Cui R; Lyu C; Li Q; Jiang Y; Mou N; Yang Z; Liu X; Deng Q; Li L
    Hematol Oncol; 2021 Feb; 39(1):75-86. PubMed ID: 32949412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T in adult ALL: When and for whom?
    Connor MP; Frey NV
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101256. PubMed ID: 33762110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CAR-T therapy for pediatric acute lymphoblastic leukemia].
    Sakaguchi H
    Rinsho Ketsueki; 2023; 64(11):1440-1446. PubMed ID: 38072432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
    Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.
    Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P
    Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent research on chimeric antigen receptor T cells in children with refractory/relapsed acute lymphoblastic leukemia].
    Wei N; Chen TP
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Feb; 25(2):210-216. PubMed ID: 36854700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [CAR-T therapy for adult B-cell acute lymphoblastic leukemia].
    Goto H
    Rinsho Ketsueki; 2023; 64(11):1432-1439. PubMed ID: 38072431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?
    Taraseviciute A; Broglie L; Phelan R; Bhatt NS; Becktell K; Burke MJ
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):337-344. PubMed ID: 30973486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.
    Martínez-Romera I; Galán-Gómez V; González-Martínez B; Guerra García P; San Román Pacheco S; Corral Sánchez D; Mozo Del Castillo Y; Bueno Sánchez D; Sisinni L; González Guerrero A; Castellano Dámaso S; Sánchez Zapardiel E; Ruz Caracuel B; Balas Pérez A; Pérez-Martínez A
    Front Immunol; 2022; 13():960412. PubMed ID: 36003375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report.
    Wen S; Niu Z; Xing L; Wang Y; Li H; Kuang N; Luo J; Zhang X; Wang F
    BMC Cancer; 2018 Nov; 18(1):1143. PubMed ID: 30458755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL.
    Hucks G; Rheingold SR
    Blood Cancer J; 2019 Jan; 9(2):10. PubMed ID: 30670684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis.
    Nagle K; Tafuto B; Palladino Kim L; Parrott JS
    Med Oncol; 2018 Sep; 35(11):144. PubMed ID: 30206753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow up post CD19 CAR-T therapy.
    Chen M; Fu M; Wang A; Wu X; Zhen J; Gong M; Zhang X; Yue G; Du Q; Zhao W; Zhao Y; Lu P; Wang H
    Leuk Lymphoma; 2022 Feb; 63(2):426-434. PubMed ID: 34672246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.
    Ghorashian S; Amrolia P; Veys P
    Exp Hematol; 2018 Oct; 66():5-16. PubMed ID: 30031849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
    Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
    Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.